TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49. Details of the upcoming presentations are outlined below.

Poster Presentation Title: MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide

• Presentation Date/Time: Sunday, April 14, from 5:30 PM - 6:30 PM MST
• Session: P3: Multiple Sclerosis: Therapeutics and Symptom Management
• Abstract Number/Poster Number: 6567/001 in Neighborhood 6
• Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY

Poster Presentation Title: Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

• Presentation Date/Time: Wednesday, April 17, from 8:00 AM - 9:00 AM MST
• Session: P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
• Abstract Number/Poster Number: 6023/017 in Neighborhood 6
• Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida

Poster Presentation Title: Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Nave Participants in ULTIMATE I and II

• Presentation Date/Time: Wednesday, April 17, from 8:00 AM - 9:00 AM MST
• Session: P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
• Abstract Number/Poster Number: 6400/001 in Neighborhood 6
• Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida

Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.